Research

Hormonal

MC4R agonists significantly reduce triglyceride and LDL-C levels, and lower systolic blood pressure, but have no significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure.

MC4R agonists not only help you lose weight but also significantly improve your lipid profile by lowering triglycerides and LDL cholesterol, and they can lower systolic blood pressure. However, they do not appear to have a significant effect on fasting blood sugar, HbA1c, or diastolic blood pressure. These metabolic benefits make them a valuable treatment for reducing overall cardiovascular risk in patients with obesity.

GoodQualifiesHIGH confidence
These agents reduced triglyceride levels by − 35.53 mg/dL and LDL-C levels by − 9.14 mg/dL... Systolic blood pressure declined by − 4.38 mmHg, while diastolic pressure showed no meaningful change. The effect of MC4R agonists on FBS was not statistically significant.
Yanan Sun et al. · Diabetology & Metabolic Syndrome · 2025

Why this rating

Meta-analysis of 12 clinical trials, with robust findings for lipid and blood pressure outcomes.

Source

The effect of melanocortin-4 receptor agonist drugs on obesity and metabolic risk factors: a systematic review and meta-analysis

Yanan Sun et al. · Diabetology & Metabolic Syndrome · 2025

DOI 10.1186/s13098-025-02071-2

Meta-analysis · 12 studiesCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →